Navigating the challenge of tumor heterogeneity in cancer therapy

Cancer Discovery

Volumn 4, Issue 2, 2014, Pages 146-148

  Fedele, Clare ^a,b   Tothill, Richard W ^a,b   McArthur, Grant A ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CHLORAMBUCIL; IRINOTECAN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER GROWTH; CANCER THERAPY; CARCINOGENIC ACTIVITY; CELL HETEROGENEITY; CELL POPULATION; CLINICAL DECISION MAKING; COMPUTER SIMULATION; DISEASE CONTROL; DNA REPAIR; DRUG SENSITIVITY; GENE MUTATION; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; TREATMENT RESPONSE;

ANIMALS; FEMALE; GENETIC HETEROGENEITY; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS;

EID: 84896728187     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-13-1042     Document Type: Article

References (10)

1. Nowell PC. The clonal evolution of tumor cell populations. Science 1976; 194: 23-8.
2. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319: 525-32.
3. Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013; 501: 338-45.
4. DeVita VT Jr, Young RC, Canellos GP. Combination versus single agent chemotherapy: a review of the basis for selection of drug treatment of cancer. Cancer 1975; 35: 98-110.
5. Zhao B, Pritchard JR, Lauffenburger DA, Hemann MT. Addressing genetic tumor heterogeneity through computationally predictive combination therapy. Cancer Discov 2014;4:166-74.
6. Jiang H, Pritchard JR, Williams RT, Lauffenburger DA, Hemann MT. A mammalian functional-genetic approach to characterizing cancer therapeutics. Nat Chem Biol 2011;7:92-100.
7. Pritchard JR, Bruno PM, Gilbert LA, Capron KL, Luaffenburger DA, Hemann MT. Defining principles of combination drug mechanisms of action. Proc Natl Acad Sci U S A 2013;110:E170-9.
8. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012; 483: 603-7.
9. Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res 2013; 41: D955-61.
10. Hutchinson L, Kirk R. High drug attrition rates-where are we going wrong? Nat Rev Clin Oncol 2011; 8: 189-90.